Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.
Today, we return to Filament Health (FH.NEO), a Canadian-based company focusing on the natural extraction of the psychedelics compound known as psilocybin. They are steadily building an IP portfolio for natural extractions, clinical grade formulations, dosage control and enhanced drug delivery.
Enjoy!
Filament Health (FH.NEO) – Investor Roundtable Video #7